Skip to main content
SpringerLink
Log in

Vers la personnalisation de la prise en charge du psoriasis Journées dermatologiques de Paris 2020

  • Compte Rendu
  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Les références

  1. Augustin M, Alvaro-Gracia JM, Bagot M, et al. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol 2012; 26(s4): 1–16.

    Article  Google Scholar 

  2. Warren RB, Kleyn CE, Gulliver WP. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol 2011; 164(Suppl 1): 1–14.

    Article  Google Scholar 

  3. Linder D, Dall’olio E, Gisondi P, et al. Perception of disease and doctor-patient relationship experienced by patients with psoriasis: a questionnaire-based study. Am J Clin Dermatol 2009; 10(5): 325–30.

    Article  Google Scholar 

  4. Richard M-A, Corgibet F, Beylot-Barry M, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the «OBJECTIFS PEAU» study. J Eur Acad Dermatol Venereol 2018; 32(11): 1967–71.

    Article  Google Scholar 

  5. Maccari F, Fougerousse A-C, Esteve E, et al. Crossed looks on the dermatologist’s position and the patient’s preoccupations as to psoriasis and pregnancy: preliminary results of the PREGNAN-PSO study. J Eur Acad Dermatol Venereol 2019; 33(5): 880–5.

    Article  CAS  Google Scholar 

  6. Murase JE, et al. Psoriasis, pregnancy and shared decision making. Challenges experienced by dermatologists. EADV congress, 2020.

  7. Lebwohl M, Van Voorhees AS, Siegel M, et al. A comprehensive survey assessing the family planning needs of women with psoriasis. IFPA, 2018.

  8. Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med 2012; 10: 82.

    Article  Google Scholar 

  9. Bandoli G, Johnson DL, Jones KL, et al. Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. Br J Dermatol 2010; 163(2): 334–9.

    Article  CAS  Google Scholar 

  10. Meeuwis KAP, de Hullu JA, van de Nieuwenhof HP, et al. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol 2011; 164(6): 1247–55.

    Article  CAS  Google Scholar 

  11. Hawro M, Maurer M, Weller K, et al. Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis. J Am Acad Dermatol 2017; 76(4): 648–654.e2.

    Article  Google Scholar 

  12. Seeger JD, Lanza LL, West WA, Fernandez C, Rivero E. Pregnancy and pregnancy outcome among women with inflammatory skin diseases. Dermatology 2007; 214(1): 32–9.

    Article  Google Scholar 

  13. Gonzalez-Cantero A, Carretero G, Rivera R, et al. Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population. Br J Dermatol 2019; 181(5): 1085–7.

    Article  CAS  Google Scholar 

  14. McBride S, et al. Impact of psoriasis disease on family planning in women aged 18–45: results from a multinational survey across 11 countries in Europe. EADV congress, 2020.

  15. De Simone C, Calabrese L, Balato A, et al. Psoriasis and its management in women of childbearing age: tools to increase awareness in dermatologists and patients. G Ital Dermatol E Venereol 2020; 155(4): 43440.

    Google Scholar 

  16. Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effecton psoriasis in pregnancyand postpartum. ArchDermatol 2005; 141(5):601–6.

    CAS  Google Scholar 

  17. Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: a review (I). Actas Dermosifiliogr 2014; 105(8): 734–43.

    Article  CAS  Google Scholar 

  18. Amatore F, Villani A-P, Tauber M, Viguier M, Guillot B. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol 2019; 33(3): 464–83.

    Article  CAS  Google Scholar 

  19. Nast A, Amelunxen L, Augustin M, et al. S3 Guideline for the treatment of psoriasis vulgaris, update — Short version part 2 — Special patient populations and treatment situations. J Dtsch Dermatol Ges 2018; 16(6): 806–13.

    PubMed  Google Scholar 

  20. Lambert JLW, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1). J Eur Acad Dermatol Venereol 2020; 34(8): 1654–65.

    Article  CAS  Google Scholar 

  21. Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol 2020; 183(4): 628–37.

    Article  CAS  Google Scholar 

  22. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17-A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol 2014; 71(1): 141–50.

    Article  CAS  Google Scholar 

  23. Watanabe H, Kawaguchi M, Fujishima S, et al. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. J Invest Dermatol 2009; 129(3): 650–6.

    Article  CAS  Google Scholar 

  24. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61(3): 451–85.

    Article  CAS  Google Scholar 

  25. Prinz I, Sandrock I, Mrowietz U. Interleukin-17 cytokines: Effectors and targets in psoriasis-A breakthrough in understanding and treatment. J Exp Med 2020; 217(1): e20191397.

    Article  Google Scholar 

  26. Kolbinger F, Loesche C, Valentin M-A, et al. β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J Allergy Clin Immunol 2017; 139(3): 923–932.e8.

    Article  CAS  Google Scholar 

  27. Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect 2013; 2(1): 1–5.

    Article  Google Scholar 

  28. Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis 2018; 77(4): 523–32.

    Article  CAS  Google Scholar 

  29. Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol 2020; 11: 1894.

    Article  CAS  Google Scholar 

  30. Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol 2017; 83(5):991–1001.

    Article  CAS  Google Scholar 

  31. Krueger, et al. Genome Informatics. 2020.

  32. Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS One 2019; 14(8): e0220868.

    Article  CAS  Google Scholar 

  33. Reich K, et al. Matched-adjusted indirect comparison. Etude Eclipse et Ixora-R. EADV congress, 2020.

  34. Warren RB, Hansen JB, Reich K, Paul C, Puig L. Complete clearance and psoriasis area and severity index response for brodalumab and ustékinumab in AMAGINE-2 and -3. J Eur Acad Dermatol Venereol 2021; 35(2): 450–7.

    Article  CAS  Google Scholar 

  35. Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol 2020. doi: https://doi.org/10.1111/bjd.19509, Online ahead of print.

  36. Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol 2021; 184(1): 50–9.

    Article  CAS  Google Scholar 

  37. Warren R, Blauvelt A, Bagel J, et al. Bimekizumab efficacy and safety versus adalimumab in patients with moderate to severe plaque psoriasis: rsults from a multicentre, randomised, double-blinded active comparator-controlled phase 3 trial (BE SURE). EADV congress, 2020.

  38. Reich K, et al. Efficacy and safety of bimékizumab in patients with moderate-to-severe plaque psoriasis: results from BE VIVID, a 52-week Phase 3, randomized, double blinded, ustekinumab- and placebo-controlled study. AAD congress, 2020.

Download references

Author information

Authors and Affiliations

  1. Service de dermatologie, CHU Brest, Brest, France

    Émilie Brenaut

  2. Laboratoire interactions épithéliums neurones, EA 4685, Brest, France

    Émilie Brenaut

Authors
  1. Émilie Brenaut
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Émilie Brenaut.

Additional information

Liens d’intérêt

L’auteur déclare n’avoir aucun lien d’intérêt en rapport avec cet article.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brenaut, É. Vers la personnalisation de la prise en charge du psoriasis Journées dermatologiques de Paris 2020. Eur J Dermatol 31 (Suppl 1), 18–24 (2021). https://doi.org/10.1684/ejd.2021.3993

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2021.3993

Search

Navigation